Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
BackgroundHeart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure worldwide. However, no unequivocally effective treatment for HFpEF has been identified in clinical trials. In this study, we report that Astragaloside IV (AS-IV) can be used to tre...
Saved in:
| Main Authors: | Xiao Wang, Xinting Chen, Yuting Wang, Xinyu He, Lan Li, Xiaodan Wang, Yuting Huang, Guanwei Fan, Jingyu Ni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1467132/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01) -
Predictive value of NT pro BNP for new‐onset atrial fibrillation in heart failure and preserved ejection fraction
by: Xiao Liu, et al.
Published: (2024-12-01) -
Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
by: Min Chen, et al.
Published: (2024-12-01) -
Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01) -
A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
by: Björn Eriksson, et al.
Published: (2024-12-01)